Results 31 to 40 of about 10,168 (235)

The Cellular and Molecular Immunotherapy in Prostate Cancer

Vaccines, 2022
In recent history, immunotherapy has become a viable cancer therapeutic option. However, over many years, its tenets have changed, and it now comprises a range of cancer-focused immunotherapies. Clinical trials are currently looking into monotherapies or
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, D. S. Prabakaran, Raja Ganesan, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Sabariswaran Kandasamy, Thiyagarajan Ramesh, Abilash Valsala Gopalakrishnan   +9 more
doaj   +1 more source

Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy [PDF]

Science Advances, 2020
A prodrug hydrogelator serves as an effective immune booster for checkpoint blocker–based cancer immunotherapy.
Feihu Wang, Dongqing Xu, Hao Su, Weijie Zhang, Xuanrong Sun, Maya K. Monroe, Rami W. Chakroun, Zongyuan Wang, Wenbing Dai, Richard Oh, Han Wang, Qin Fan, Fengyi Wan, Honggang Cui   +13 more
openaire   +2 more sources

Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness

Frontiers in Immunology, 2023
Immune checkpoint blockade represents the latest revolution in cancer treatment by substantially increasing patients’ lifetime and quality of life in multiple neoplastic pathologies.
Chiara Ursino, Cécile Mouric, Laurent Gros, Nathalie Bonnefoy, Julien Faget   +4 more
doaj   +1 more source

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. [PDF]

Nat Commun, 2018
Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA.   +21 more
europepmc   +2 more sources

Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma

Scientific Reports, 2018
DNA vaccination against cancer has become a promising strategy for inducing a specific and long-lasting antitumor immunity. However, DNA vaccines fail to generate potent immune responses when used as a single therapy.
Alessandra Lopes, Kevin Vanvarenberg, Špela Kos, Sophie Lucas, Didier Colau, Benoît Van den Eynde, Véronique Préat, Gaëlle Vandermeulen   +7 more
doaj   +1 more source

The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma

Biomedicines, 2022
Immunotherapies with immune checkpoint inhibitors or adoptive cell transfer have become powerful tools to treat cancer. These treatments act via overcoming or alleviating tumor-induced immunosuppression, thereby enabling effective tumor clearance ...
Mitrajit Ghosh, Anna M. Lenkiewicz, Bozena Kaminska   +2 more
doaj   +1 more source

Immune checkpoint: The novel target for antitumor therapy

Genes and Diseases, 2021
Inhibitory checkpoint molecules include programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), human endogenous retrovirus-H Long terminal repeat-associating 2 (HHLA2), B7 homolog 4 protein (B7 ...
Xianghu Jiang, Guohong Liu, Yirong Li, Yunbao Pan   +3 more
doaj   +1 more source

Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology

Frontiers in Oncology, 2018
The tumor microenvironment (TME) is a multifaceted ecosystem characterized by profound cellular heterogeneity, dynamicity, and complex intercellular cross-talk.
Francesca Finotello, Federica Eduati
doaj   +1 more source

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

npj Precision Oncology, 2021
A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer.
Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain   +10 more
doaj   +1 more source

Trial watch: Toll-like receptor ligands in cancer therapy

OncoImmunology, 2023
Accumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists have been approved by regulatory agencies for use in oncological applications.
Julie Le Naour, Guido Kroemer
doaj   +1 more source